Effect of Complete Remission and Responses Less Than Complete Remission on Survival in Acute Myeloid Leukemia: A Combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D.
From February 2001 to February 2002, 946 patients with advanced GI stromal tumors (GISTs) treated with imatinib were included in a controlled EORTC/ISG/AGITG (European Organisation for Research and ...
HealthDay News — The FDA has expanded indications for imatinib mesylate tablets (Gleevec, Novartis) to include treatment of adults who have undergone surgical removal of CD117-positive ...
Novartis Pharmaceutical Corp. of East Hanover today announced that new data from a large, international clinical trial found promising results with certain leukemia patients.Novartis Pharmaceutical ...
Conventional karyotyping was performed on the BM diagnostic aspirate after short-term culture (24–72 h). The chromosomes were analyzed after R and/or G-banding. All karyotypes were reported according ...
Gleevec remains effective in advanced GIST, with median overall survival of 75.3 months and significant long-term survival rates. Factors like female sex, gastric tumor location, smaller tumors, and ...
Lead CML researcher discusses the evolution of a groundbreaking treatment and its effect on patient survival. When imatinib (Gleevec; Novartis), the first-ever tyrosine kinase inhibitor, made its ...
A New York Times health reporter explains what clinical trials are, why they are important and how they can help inform us. Credit...Ricardo Tomás Supported by By Nina Agrawal Nina Agrawal is a health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results